Company: IMRX
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001790340-25-000053
Chunk: 43

Company: Immuneering Corp
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 43
---
 non-revocation of a separation agreement and release with the Company and compliance with restrictive covenants contained therein, Mr. Bookman will be entitled to receive, in lieu of the payments and benefits described above, (a) continued payment of Mr. Bookman’s base salary for 12 months, (b) any unpaid bonus earned for the year prior to the year of termination, (c) a payment equal to 1.0 times Mr. Bookman’s target annual bonus for the year of termination, (d) direct payment of or reimbursement for COBRA premiums, less the amount Mr. Bookman would have paid for coverage as an active employee, for up to 12 months and (e) accelerated vesting of all equity or equity-based awards that vest solely based on Mr. Bookman’s continued employment or service with the Company.

Mr. Bookman is party to a restrictive covenant agreement, pursuant to which he has agreed to refrain from competing with us or soliciting our customers or employees during his employment and for one year following termination of his employment and from disclosing our proprietary information during or at any time following his employment.

#### Director Compensation
We maintain a compensation program for our non-employee directors under which each non-employee director receives compensation for their services on our Board of Directors. The program is periodically reviewed by our compensation committee and our Board of Directors and for 2024 provided for equity and payments of the following amounts:

• an option to purchase 35,000 shares of our Class A common stock (increased to 66,700 shares effective May 21, 2024) upon the director’s initial election or appointment to our Board of Directors;

• for a director who will continue to serve after our annual meeting of stockholders, an option to purchase 17,500 shares of our Class A common stock on the date of such annual meeting (increased to 33,350 shares effective May 21, 2024), provided that, if the director has been serving as a non-employee director for less than six months as of the date of such annual meeting, the number of shares underlying the option is reduced on a pro-rata basis based on the number of months such director has served as a non-employee director during the twelve month period ending on the date of such meeting;

• an annual director fee of $40,000 (the “Base Retainer”); and

• if the director serves on a committee of our Board of Directors or in the other capacities stated below,